Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
INDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $3.10
Previous CloseN/A
Volume47.54K
Average Volume (3M)824.78K
Market Cap
$6.78M
Enterprise Value$3.63M
Total Cash (Recent Filing)$9.74M
Total Debt (Recent Filing)$153.13K
Price to Earnings (P/E)―
Beta1.82
Next Earnings
May 08, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding14,429,244
10 Day Avg. Volume419,188
30 Day Avg. Volume824,780
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$5.00Price Target Upside986.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Safety Review Committee cleared the study for unrestricted enrollment, indicating good safety signals and allowing for increased enrollment.
Partnership And CollaborationIndaptus signed a clinical supply agreement with BeiGene for its PD-1, tislelizumab, which could enhance the study by potentially combining treatments.
Preclinical SuccessPreclinical work has shown that Decoy20, in combination with PD1 and a non-steroidal anti-inflammatory agent, induces tumor eradication rates of 80-100%.
Bears Say
Financial StabilityThe cash balance is getting low; Indaptus needs to raise capital soon and potential dilution is being factored in.
Price TargetThe positive outlook on the Decoy20 program and Indaptus remains unchanged despite the lowered price target.
---
Ownership Overview
11.51% Insiders
2.38% Mutual Funds
1.51% Other Institutional Investors
82.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INDP FAQ
What was Indaptus Therapeutics’s price range in the past 12 months?
Indaptus Therapeutics lowest stock price was $0.46 and its highest was $3.10 in the past 12 months.
What is Indaptus Therapeutics’s market cap?
Indaptus Therapeutics’s market cap is $6.78M.
When is Indaptus Therapeutics’s upcoming earnings report date?
Indaptus Therapeutics’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Indaptus Therapeutics’s earnings last quarter?
Indaptus Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.1.
Is Indaptus Therapeutics overvalued?
According to Wall Street analysts Indaptus Therapeutics’s price is currently Undervalued.
Does Indaptus Therapeutics pay dividends?
Indaptus Therapeutics does not currently pay dividends.
What is Indaptus Therapeutics’s EPS estimate?
Indaptus Therapeutics’s EPS estimate is -0.18.
How many shares outstanding does Indaptus Therapeutics have?
Indaptus Therapeutics has 14,429,244 shares outstanding.
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Indaptus Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Indaptus Therapeutics?
Currently, no hedge funds are holding shares in INDP
---
Company Description
Indaptus Therapeutics
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
---
INDP Stock 12 Month Forecast
Average Price Target
$5.00
▲(986.96% Upside)
Technical Analysis
AIM ImmunoTech
―
Acurx Pharmaceuticals
―
Ocean Biomedical
―
Apollomics
―
Meihua International Medical Technologies Co., Ltd.
―
Best Analysts Covering INDP
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-49.79%
reiterated a buy rating 23 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -49.79% per trade.
---